- Home
- MACK
as 05-20-2024 4:00pm EST
Merrimack Pharmaceuticals Inc is a biotechnology company that discovers, develops, and commercializes innovative medicines that consist of novel therapeutics paired with diagnostics to treat cancer. The company's core approach to systems biology is to apply multidisciplinary capabilities to build functional and predictive computational models of biological systems, such as cell signaling networks. Merrimack also enters into third-party agreements to further process and commercialize its products.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 223.7M | IPO Year: | 2012 |
| Target Price: | N/A | AVG Volume (30 days): | 199.8K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 13.87 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.53 - $15.89 | Next Earning Date: | 05-15-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Share on Social Networks:
Stock Insider Trading Activity of Merrimack Pharmaceuticals Inc. (MACK)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Andersen Eric | MACK | Director | Dec 26 '23 | Buy | $13.35 | 857 | $11,441.21 | 534,008 | SEC Form 4 |
| Andersen Eric | MACK | Director | Dec 26 '23 | Buy | $13.15 | 48,693 | $640,312.95 | 533,151 | SEC Form 4 |
| Andersen Eric | MACK | Director | Dec 7 '23 | Buy | $12.85 | 76,384 | $981,519.12 | 1,735,600 | SEC Form 4 |
| Andersen Eric | MACK | Director | Dec 7 '23 | Buy | $12.85 | 24,666 | $316,953.17 | 484,458 | SEC Form 4 |
| Andersen Eric | MACK | Director | Nov 17 '23 | Buy | $12.50 | 235 | $2,937.50 | 1,659,216 | SEC Form 4 |
| Andersen Eric | MACK | Director | Nov 17 '23 | Buy | $12.50 | 65 | $812.50 | 459,792 | SEC Form 4 |
| Andersen Eric | MACK | Director | Nov 14 '23 | Buy | $12.50 | 39,283 | $491,037.50 | 1,658,981 | SEC Form 4 |
| Andersen Eric | MACK | Director | Nov 14 '23 | Buy | $12.50 | 10,887 | $136,087.50 | 459,727 | SEC Form 4 |
| Andersen Eric | MACK | Director | Nov 8 '23 | Buy | $12.13 | 4,783 | $58,027.36 | 1,569,894 | SEC Form 4 |
| Andersen Eric | MACK | Director | Nov 8 '23 | Buy | $12.13 | 9,040 | $109,673.28 | 435,037 | SEC Form 4 |
| Andersen Eric | MACK | Director | Nov 8 '23 | Buy | $12.19 | 7,810 | $95,221.86 | 1,577,704 | SEC Form 4 |
| Andersen Eric | MACK | Director | Nov 8 '23 | Buy | $12.19 | 2,165 | $26,396.33 | 437,202 | SEC Form 4 |
Latest Merrimack Pharmaceuticals Inc. News
MACK Breaking Stock News: Dive into MACK Ticker-Specific Updates for Smart Investing
Business Wire
10 days ago
Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock
Business Wire
11 days ago
Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of Dissolution
Business Wire
20 days ago
Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution
Business Wire
2 months ago
Merrimack Receives $225 Million Milestone Payment from Ipsen
Business Wire
2 months ago
Merrimack Reports Full Year 2023 Financial Results
Simply Wall St.
3 months ago
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) is definitely on the radar of hedge funds investors who own 35% of the company
Business Wire
3 months ago
Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
GlobeNewswire
4 months ago